PPARα agonists(Peroxisome proliferator-activated receptor α agonists), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists), PPARδ agonists(Peroxisome proliferator-activated receptor delta agonists)

Therapeutic Areas

Digestive System DisordersOther DiseasesImmune System Diseases+ [2]

Active Indication

Fibrosis, LiverInflammationLiver Cirrhosis+ [3]

Inactive Indication

Bladder CancerIdiopathic Pulmonary FibrosisScleroderma, Diffuse

Originator Organization

AbbVie, Inc.

Active Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Inventiva SA

AbbVie, Inc.

+ [1]

Inactive Organization

Abbott Products LLC

Solvay Pharmaceuticals, Inc.

License Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

L'Université d'Angers

Inventiva SA

Drug Highest PhasePhase 3

First Approval Date-

RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (European Union), Breakthrough Therapy (China)

Structure/Sequence

Molecular FormulaC19H15ClN2O4S2

InChIKeyOQDQIFQRNZIEEJ-UHFFFAOYSA-N

CAS Registry927961-18-0

Clinical Trials associated with Lanifibranor

CTIS2025-524385-18-00

/ CompletedPhase 1

A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor

Start Date11 Feb 2026

Sponsor / Collaborator

Inventiva SA

JPRN-jRCT2031240629

/ Not yet recruitingPhase 1

Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of IVA337 in Healthy Japanese Adults

Start Date01 Feb 2025

Sponsor / Collaborator-

NCT06126562

/ CompletedPhase 1

A Phase I Clinical Study to Evaluate the Pharmacokinetic Profile and Safety of Lanifibranor After Single Dose and Multiple Doses in Healthy Adult Chinese Subjects

This will be a randomized, open-label parallel design and single centre study conducted at the 1st hospital affiliated to Jilin University. Approximately 24 healthy Chinese volunteers, male and female will be recruited and divided into two equal groups (12 subjects per dose). The primary objective of this study is to evaluate the pharmacokinetic profile of lanifibranor after single dose and multiple doses 800 and 1200 mg in healthy adult Chinese subjects. The secondary objective is to evaluate the safety of lanifibranor after single dose and multiple doses 800 and 1200 mg in healthy adult Chinese subjects.

Start Date31 Oct 2023

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with Lanifibranor

100 Translational Medicine associated with Lanifibranor

100 Patents (Medical) associated with Lanifibranor

Literatures (Medical) associated with Lanifibranor

01 Dec 2026·VASCULAR PHARMACOLOGY

Pan-peroxisome proliferator-activated receptor agonist IVA337 alleviates secondary lymphedema via inhibiting TGFβ/SMAD2/3 signaling pathway

Article

Author: Autieri, Michael ; Delgado, Esteban ; Zhao, Jianan ; Liu, Xiaolei ; Liu, Hongxia ; Yang, Xiaofeng ; Pang, Jingjing ; Flynn, Liam ; Do, Long Nguyen Hoang

Lymphedema is a chronic disease characterized by impaired lymph drainage and accumulation of protein-rich interstitial fluid, which progresses to develop irreversible fibrosis. Despite its substantial clinical burden, effective pharmacological therapies that improve lymphatic function and prevent disease progression remain lacking. Given the prominent inflammatory and fibrotic responses associated with lymphedema, we investigated the therapeutic potential of IVA337 (lanifibranor), a pan-peroxisome proliferator-activated receptor (PPAR) agonist that activates PPARα, PPARβ/δ, and PPARγ, key regulators of lipid metabolism, inflammation, and fibrosis. Here, we evaluated the therapeutic efficacy of IVA337 during the early stage of surgery-induced secondary lymphedema in mice and investigated the underlying mechanisms. IVA337 administration alleviates lymphedema progression, improves lymphatic drainage, reduces dermal thickness, and resolves lymphatic vessel dilation. Mechanistically, IVA337 suppresses TGFβ/SMAD2/3 signaling pathway, reduces immune cells infiltration, and improves lymphatic vessels integrity. In human dermal lymphatic endothelial cell (HDLEC), IVA337 attenuates TGFβ induced SMAD2/3 phosphorylation and preserves the expression of cell junction Claudin5, reduces VE-Cadherin-stained cell-cell gaps. Collectively, our findings demonstrate that IVA337 protects against early-stage lymphedema by suppressing TGFβ/SMAD2/3 signaling and limiting inflammatory and fibrotic and lymphatic endothelial dysfunction. These findings identify pan-PPAR activation as a promising pharmacological strategy to preserve lymphatic function during the early phase of lymphedema and potentially prevent progressive tissue fibrosis.

01 Dec 2026·BIOCHEMICAL PHARMACOLOGY

Combination pharmacotherapy for MASH: Potential synergistic approaches

Review

Author: Holleboom, Adriaan G ; Meije, Dana A ; van de Graaf, Stan F J

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent and severe liver disease globally, encompassing a spectrum from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), the progressive inflammatory form that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The multifaceted pathogenesis of MASH, particularly in the setting of obesity and type 2 diabetes mellitus (T2DM), has resulted in the exploration of pharmaca that target metabolic, inflammatory, and fibrotic processes. Until quite recently, demonstrating efficacy in phase 3 trials with single agents has been challenging. Multiple combination trials have been conducted, often requiring complex multi-arm designs, but demonstrating limited additive benefit over monotherapy. The recent conditional approval of two monotherapies targeting metabolic pathways, the thyroid hormone receptor beta agonist (THRβ) resmetirom and the glucagon-like peptide 1 receptor agonist (GLP1 RA) semaglutide, is kickstarting the therapeutic armamentarium for MASH. Other promising monotherapies may follow in the near future, in particular fibroblast growth factor 21 (FGF21) analogues and pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist lanifibranor. As a result, the position of combination therapy in MASH may shift toward add-on strategies evaluated in clinical practice rather than pharma-driven trial settings. The four monotherapy classes mentioned may be applied in combination, as is already occurring with resmetirom and semaglutide. In this review, we break down the rationale for the various combinations. In addition, we highlight the unmet need for effective antifibrotic therapies and discuss future directions for combination therapy in MASH. Based on the available data, we provide recommendations for the most promising combination strategies.

01 Oct 2026·Advanced Healthcare Materials

Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF‐β Axis Inhibition and Ferroptosis Induction

Article

Author: Zhang, Mengmeng ; Mu, Mengyao ; Ma, Pengju ; Liu, Hui ; Sun, Xiao ; Gao, Wenshuang ; Wang, Yingqi ; Yang, Yinuo ; Li, Wenzhe ; Ren, Ke ; Zhu, Qiang ; Xu, Xueli

ABSTRACT:

Liver fibrosis and its terminal stage, cirrhosis, represent a major cause of morbidity and mortality related to hepatic pathologies. Activated hepatic stellate cells (aHSCs) are the principal drivers of fibrogenesis and therefore constitute key therapeutic targets. Lanifibranor, a pan‐peroxisome proliferator‐activated receptor agonist, has shown promising antifibrotic efficacy; however, its clinical application is limited by rapid systemic clearance and insufficient accumulation in fibrotic liver tissue. In this study, we report an aHSC‐targeted nanoplatform for lanifibranor delivery based on vitamin A‐functionalized two‐dimensional iron sulfide nanosheets (FeS‐V A @lanifibranor, FVL). Lanifibranor was electrostatically loaded onto vitamin A‐modified FeS nanosheets, enabling selective uptake by aHSCs and enhancing hepatic accumulation of lanifibranor. FVL significantly downregulated the expression of key fibrogenic markers and markedly reduced collagen accumulation. Mechanistically, the therapeutic efficacy of FVL arises from a dual‐action mechanism: inhibition of SMAD2/3 phosphorylation within the transforming growth factor‐β (TGF‐β) signaling pathway and induction of ferroptosis in aHSCs. In conclusion, this study provides an effective aHSC‐specific nanotherapeutic strategy for liver fibrosis treatment and highlights the translational potential of FVL nanoplatforms for targeted antifibrotic therapy.

137

News (Medical) associated with Lanifibranor

07 Oct 2026

·www.biospace.com

Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026

Preclinical data showed that balanced PPARα, PPARδ and PPARγ activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesis Preclinical data and Phase 2b clinical results showed lanifibranor improved liver sinusoidal endothelial cell alterations and was associated with changes in intrahepatic vascular abnormalities across multiple stages of disease Analysis of plasma cell-free DNA (cfDNA) identified coordinated epigenetic changes across the PPAR family in patients with MASLD, supporting the biological rationale for targeting multiple PPAR isoforms Daix (France), New York City (New York, United States), October 6, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral small molecule therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of three abstracts at the upcoming AASLD The Liver Meeting ® 2026, to be held from November 5-9, 2026, in Denver, Colorado. The abstracts provide further characterization of the biological rationale for the balanced pan-PPAR approach of lanifibranor, highlighting complementary activities observed across multiple hepatic cell populations and pathways implicated in MASH pathophysiology. Together with the clinical and preclinical findings, including metabolic dysfunction, inflammation, fibrosis and liver sinusoidal endothelial alterations, these findings provide translational insights into the potential for simultaneous engagement of PPARα, PPARδ and PPARγ to address multiple interconnected drivers of MASH pathophysiology. Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis, with topline results expected in the fourth quarter of this year. Details of the Presentations are as Follows: Abstract Title: Coordinated Methylation Across PPAR Isoforms in Plasma Cell-free DNA Reflects Pathway-wide Epigenetic Dysregulation in MASLD and Supports a Pan-PPAR Therapeutic Rationale Publication #: 1052 Presentation Type: Poster Authors: M. Abdelmalek; Soheil Damangir; G. Wettstein; Amin Naghdloo; C. Lu; L. Bazargan; H. Amini; A. Diehl Date: November 5, 2026 Abstract Title: Lanifibranor Targets Multiple Hepatic Cell Populations to Reduce Fibrosis Through Balanced Pan-PPAR Activation Publication #: 3570 Presentation Type: Poster Authors: Guillaume Wettstein; Sander Lefere; Jordi Gracia-Sancho; Frank Tacke; Manal F. Abdelmalek; Sven M. Francque Date: November 7, 2026 Abstract Title: Lanifibranor Improved Liver Sinusoidal Endothelial Cell Dysfunction and Vascular Alterations Across All Stages From MASH To Cirrhosis Publication #: 3552 Presentation Type: Poster Authors: Guillaume Wettstein; Pierre-Emmanuel Rautou; Shivani Chotkoe; Wilhelmus J. Kwanten; Valerie Paradis; Jordi Gracia-Sancho; Manal F. Abdelmalek; Sven M. Francque Date: November 7, 2026 In addition, Inventiva will be present at the Congress at Booth # 1344. About Lanifibranor Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding pro to the favorable tolerability pro has been observed in clinical trials and preclinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts Investor Relations David Nikodem: IR@inventivapharma.com Media Relations Lisa Buffington: media@inventivapharma.com Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “estimate,” “may,” “will,” “could,” “should,” “designed,” “hope,” “target,” “potential,” “opportunity,” “possible,” “aim,” and “continue” or similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical fact, included in this press release are forward-looking statements. These statements include, but are not limited to, statements concerning the potential therapeutic benefit of lanifibranor, the expected availability and timing of results from NATiV3, the timing of potential regulatory submissions, approvals and commercialization of lanifibranor, Inventiva’s cash resources and expenses and ability to obtain additional financial resources, including assumptions and conditions relating thereto with, and Inventiva's future activities, expectations, plans, growth and prospects. Although Inventiva’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that such forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Inventiva, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, contingencies and uncertainties include, among other things, uncertainties inherent in research and development, clinical data and analysis and decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any product candidates, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; Inventiva’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; Inventiva’s ability to achieve milestones; Inventiva’s ability to obtain adequate financing to fund its operations and continue as a going concern, including Inventiva’s ability to enter into potential transactions on the expected timing or at all, Inventiva’s ability to comply with and satisfy the terms and conditions of its financing documents and whether, when and to what extent the securities issued in the Debt Financing and other dilutive instruments, including the Tranche 3 warrants, may be exercised; Inventiva’s ability to execute on its strategy, including with respect to commercialization, marketing and manufacturing; potential negative impacts on Inventiva from changes in laws and regulations, unfavorable conditions in its industry, geopolitical events, and ongoing conflicts, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, and the other risks and uncertainties described in Inventiva’s Universal Registration Document for the year ended on December 31, 2025 filed with the Autorité des Marchés Financiers on April 8, 2026, Inventiva’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on April 8, 2026 and Inventiva’s Half-Year Report for the fiscal period ended June 30, 2026, filed on Form 6-K on September 28, 2026 including those described under the caption "Risk Factors", and in future filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Inventiva disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that Inventiva becomes aware of, except as required by law. Attachment INVENTIVA AALSD Abstracts PR EN 10.6.2026

Phase 2Fast TrackPhase 3Clinical ResultBreakthrough Therapy

28 Sep 2026

·www.biospace.com

Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 1 as of June 30, 2026 Cash runway guidance remains unchanged from July 30, 2026 2 Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026 Key highlights from the first half of 2026 and recent Company updates Management to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first half of 2026, ended June 30, 2026, including its cash position, cash flows and revenues, and provided a corporate update. Key Financial Results for the First Half of 2026 (in thousands of euros) Six Months Ended June 30, 2026 June 30, 2025 Revenues 20 4,454 Other income 1,286 1,156 Research and development expenses (46,238) (44,890) Marketing – business development expenses (2,589) (746) General and administrative expenses (22,247) (14,713) Other operating income (expenses) (619) (8,202) Net Operating Loss (70,388) (62,940) Net Financial Income (Loss) 907 (113,224) Share of net loss- Equity method and dilution gain 117 (220) Income tax (104) 503 Net Loss for the Period (69,467) (175,882) Basic/diluted loss per share (euros/share) (0.25) (1.62) Weighted average number of outstanding shares used for computing basic/diluted loss per share 273,582,870 108,839,636 There were no revenues recorded for the first half of 2026, compared to €4.5 million generated for the same period in 2025. Revenue recognized in the first half of 2025 was attributable to the 2022 License Agreement with Chia Tai Tianging Pharmaceutical Group Co., Ltd. (as amended and assigned to Chia Tai Tianging (Guangzhou) Co., Ltd). Other income amounted to €1.3 million for the first half of 2026, stable as compared to €1.2 million for the first half of 2025. Other income mainly consisted of the French research tax credit (“Crédit d’Impôt Recherche”). R&D expenses for the first half of 2026 amounted to €46.2 million, mainly driven by the clinical development of lanifibranor in MASH, up 3.0% compared to the €44.9 million for the first half of 2025. This increase was in line with operational plan expectations and did not include any preclinical research expenses following the discontinuation of preclinical R&D activities implemented mid-2025. Marketing and business development expenses amounted to €2.6 million for the first half of 2026, compared to €0.7 million for the same period in 2025, primarily reflecting increased personnel costs and expenses related to preparations for the potential commercial development of lanifibranor, if approved. General and administrative expenses (G&A) amounted to €22.2 million in the first half of 2026, compared to €14.7 million in the first half of 2025, an increase of €7.5 million. The change was primarily related to €4.7 million of increase in personnel costs, including share-based compensation expenses, consulting fees and other expenses associated with potential commercial development of lanifibranor, if approved. Net financial income (loss) amounted to €0.9 million in the first half of 2026, compared to (€113.2) million for the same period in 2025. The financial result for the first half of 2026 mainly reflected (i) €16.2 million of non-cash impact from the IFRS fair value accounting of financial instruments entered into in connection with the restructuring of warrants issued to European Investment Bank (“EIB”), the Lenders' Warrants issued to funds and accounts managed by BlackRock and Claret Capital Partners (together, the “Lenders”) and the embedded convertible option in the first tranche of €35.0 million of senior secured convertible bonds issued under the June 2026 debt financing with the Lenders for up to €130.0 million (the “Debt Financing”), (ii) €4.8 million of income from cash equivalents and foreign exchange gains (net), and (iii) (€20.0) million of interest and related financial expenses, including (€11.2) million resulting from the repayment of the loan with the EIB and (€7.4) million of interest expense related to the royalty certificates issued in 2023 and 2024. The Company’s net loss stood at (€69.5) million as of June 30, 2026, compared to (€175.9) million as of June 30, 2025. As of June 30, 2026, the Company’s cash and cash equivalents amounted to €166.1 million and €67.8 million in short-term deposits 1 , compared to cash and cash equivalents of €99.3 million and €131.6 million in short-term deposits as of December 31, 2025. Net cash used in operating activities amounted to (€45.4) million for the first half of 2026, compared to (€53.7) million for the same period in 2025. The lower cash consumption mainly reflects the favorable working capital change partially offset by the increase in operating expenses relating to the continued advancement of the NATiV3 Phase 3 clinical trial and preparation of pre-commercial activities. Net cash generated from investing activities for the first half of 2026 amounted to €63.8 million, compared to (€24.8) million for the first half of 2025. The increase primarily reflects changes in the Company's short-term deposits, including in connection with the June 2026 comprehensive refinancing transaction 3 . Net cash generated from financing activities for the first half of 2026 amounted to €47.7 million, compared to €104.8 million for the first half of 2025.The net cash generated from financing activities in the first half of 2026 reflects the comprehensive refinancing transaction announced on June 2, 2026, including the offering of 27,272,727 American Depositary Shares (the “Equity Offering”) for €103.0 million and the Tranches A and B of the Debt Financing of €75.0 million, both in gross proceeds. These cash inflows were partially offset by the repayment in full of the existing EIB loans for an aggregate amount of €62.2 million, and the repurchase of all of the warrants issued to EIB in connection with the first tranche of the EIB loans and 700,000 of the warrants issued to EIB in connection with the second tranche of the EIB loans for an aggregate repurchase price of €50.0 million 4 . The net cash generated from financing activities in the first half of 2025 came from the gross proceeds of €115.6 million (net proceeds of €108.0) of the 2024 Structured Financing 5 . Based on the Company’s existing cash and cash equivalents and short-term deposits, together with the net proceeds from the completed Equity Offering, the completed EIB Transactions and the issuance of Tranches A and B under the Debt Financing Transaction 6 , the Company expects to be able to finance its operations as currently planned until the end of the second quarter of 2027. At the date of this press release, the Company's current cash and cash equivalents are not sufficient to cover operating needs as currently planned for the next twelve months. If Tranche C of the Debt Financing Transaction 3 is issued for potential gross proceeds of up to €55.0 million and the Tranche 3 warrants previously issued by the Company in the Structured Financing 5 for potential gross proceeds of up to €116.0 million are exercised in full, the Company expects to be able to finance its operations as currently planned until the start of the first quarter of 2028 7 . Over the first half of 2026, the Company recorded a positive foreign exchange effect on cash and cash equivalents of €0.7 million, compared with a negative effect of (€0.7) million for the first half of 2025, primarily due to the changes in the EUR/USD exchange rate. Corporate Updates On September 2, 2026, Inventiva announced that the last patient had completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for the treatment of patients with MASH with moderate and advanced fibrosis 8 . NATiV3 enrolled 1,009 adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis, with an additional 410 patients enrolled in an exploratory cohort. Inventiva expects to report topline results from the Phase 3 clinical trial NATiV3 in the fourth quarter of 2026. If the NATiV3 topline results are favorable, the Company anticipates regulatory submission in the first half of 2027 and is preparing for a potential U.S. launch of lanifibranor in 2028, subject to U.S. Food and Drug Administration (“FDA”) approval. Since the start of 2026, Inventiva strengthened its leadership team with the appointment of Axel-Sven Malkomes as Chief Financial Officer, Susan Coles, as Chief Legal Officer, Pamela Herbster as Chief People Officer 9 and Chris Benecchi, as Chief Operating Officer 10 . Barbara Krebs-Pohl, Anne Prener, and Camilla Soenderby, were appointed as independent members of the Company’s Board of Directors, effective June 30, 2026, reflecting the additional expertise, international reach, and strategic acumen required to guide the Company through its next phase of development and potential commercialization 11 . First-Half Financial Results Webcast Inventiva’s management will hold a conference call in English, followed by a Q&A session, on Monday, September 28, 2026, at 8:00 AM (New York), 2:00 PM (Paris) to discuss first-half financial results for 2026. Participants wishing to join the conference call by phone and ask questions must register in advance here . Upon registration, participants will receive dial-in details by email. The live webcast may be accessed on the Events section of the Inventiva website. A replay of the conference call will be available after the event on the Company’s website. Upcoming Scientific Conference Participation The American Association for the Study of Liver Diseases (AASLD), Denver, CO, November 5-9, 2026. Next Financial Results Publication Revenues and cash and cash equivalents for the third quarter 2026 on Monday November 23, 2026 (before E.U. and U.S. market open). About Lanifibranor Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding pro to the favorable tolerability pro has been observed in clinical trials and preclinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts Investor R elations David Nikodem: IR@inventivapharma.com Media Relations Lisa Buffington: media@inventivapharma.com Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “estimate,” “may,” “will,” “could,” “should,” “designed,” “hope,” “target,” “potential,” “opportunity,” “possible,” “aim,” and “continue” or similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical fact, included in this press release are forward-looking statements. These statements include, but are not limited to, statements concerning the potential therapeutic benefit of lanifibranor, the expected availability and timing of results from NATiV3, the timing of potential regulatory submissions, approvals and commercialization of lanifibranor, Inventiva’s cash resources and expenses and ability to obtain additional financial resources, including assumptions and conditions relating thereto with, and Inventiva's future activities, expectations, plans, growth and prospects. Although Inventiva’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that such forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Inventiva, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, contingencies and uncertainties include, among other things, uncertainties inherent in research and development, clinical data and analysis and decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any product candidates, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; Inventiva’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; Inventiva’s ability to achieve milestones; Inventiva’s ability to obtain adequate financing to fund its operations and continue as a going concern, including Inventiva’s ability to enter into potential transactions on the expected timing or at all, Inventiva’s ability to comply with and satisfy the terms and conditions of its financing documents and whether, when and to what extent the securities issued in the Debt Financing and other dilutive instruments, including the Tranche 3 warrants, may be exercised; Inventiva’s ability to execute on its strategy, including with respect to commercialization, marketing and manufacturing; potential negative impacts on Inventiva from changes in laws and regulations, unfavorable conditions in its industry, geopolitical events, and ongoing conflicts, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, and the other risks and uncertainties described in Inventiva’s Universal Registration Document for the year ended on December 31, 2025 filed with the Autorité des Marchés Financiers on April 8, 2026, Inventiva’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on April 8, 2026 and Inventiva’s Half-Year Report for the fiscal period ended June 30, 2026, filed on Form 6-K on September 28, 2026 including those described under the caption "Risk Factors", and in future filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Inventiva disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that Inventiva becomes aware of, except as required by law. 1 Short-term deposits were included in the category “other current assets” in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available. 2 Cf press release of July 30, 2026. 3 Cf press release of June 2, 2026 4 Cf press releases of June 2, 2026, and June 12, 2026. 5 Cf press release of October 13, 2024. 6 Cf press release of June 2, 2026 (please refer to the description of the financial covenants pertaining to the Debt Financing). 7 These estimates are based on the Company’s current business plan and assume the successful issuance of Tranche C of the Debt Financing, and the exercise in full of the Tranche 3 warrants previously issued by the Company in the Structured Financing for potential proceeds of up to €116.0 million, and exclude any potential milestones payable to or by the Company and any additional expenditures related to the product candidate or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based these estimates on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated. These estimates may be shortened in the event of an increase, in expenditure relating to the development programs beyond the Company's expectations, or if the development program progresses more quickly than expected. 8 Cf press release of September 2, 2026. 9 Cf press release of April 22, 2026. 10 Cf press release of August 31, 2026. 11 Cf press release of July 8, 2026. Attachment Inventiva - PR - H1 2026 Financial Results - EN - 09 28 2026

Phase 3Executive ChangeFinancial StatementFast Track

08 Sep 2026

·www.biospace.com

Inventiva to Present Multiple Abstracts at Paris MASH 2026

Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic pro cardiovascular risk factors in patients with MASH with or without type 2 diabetes Preclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and cardiac pro to TZDs and dual PPARα/γ agonists Daix (France), New York (New York, United States), September 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announces the presentation of five abstracts at the 12th Paris MASH Meeting taking place September 10-11, 2026, at the Pasteur Institut in Paris, France. The abstracts present Phase 1 and Phase 2 clinical and preclinical data that further characterize the pan-PPAR pharmacological pro lanifibranor and evaluate its potential effects on systemic metabolic dysfunction associated with MASH. Clinical data from Phase 1 and Phase 2 trials demonstrated direct PPAR target engagement, as reflected by increases in adiponectin, together with improvements observed in measures of insulin sensitivity, glycemic control, lipid parameters, and selected cardiovascular risk factors, with effects observed in patients with or without Type 2 diabetes. Separate preclinical studies demonstrated improvement in hepatic and metabolic parameters, and further characterized lanifibranor’s balanced pan-PPAR pharmacology, supporting a differentiated fluid and cardiac pro the PPAR class. Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis, with topline results expected in the fourth quarter of this year. Following are the details of the poster presentations on September 10, 2026: Abstract Title: Beyond The Liver: Cardiovascular Effects of The Pan-PPAR Agonist Lanifibranor in Patients With MASH Publication Number: 1256 Authors: S. Francque, A. Holleboom, J. Campagna, S. Hogan, G. Wettstein, M. Abedelmalek Abstract Title: Metabolic Benefits of Pan-PPAR Agonist Lanifibranor in Patients With and Without Type 2 Diabetes Publication Number: 1249 Authors: A. Holleboom, M. Abdelmalek, S. Hogan, J. Campagna, G. Wettstein, S. Francque Abstract Title: Lanifibranor Improves Metabolic and Histological Features of MASH Across Multiple Preclinical Models: Convergent Pan-PPAR Activity Publication Number: 1255 Authors: A. Holleboom, S. Francque, J. Campagna, S. Hogan, G. Wettstein, M. Abedelmalek Abstract Title: Lanifibranor Phase 1/2A Experience – PPAR Engagement and Metabolic Activity Without Early Clinical Fluid Retention Publication Number: 1254 Authors: A. Holleboom, S. Hogan, J. Campagna, G. Wettstein, M. Abdelmalek, S. Franque Abstract Title: Partial PPAR Agonism Underlies Lanifibranor's Preclinical Fluid/Cardiovascular Safety Versus Full and Dual PPAR Agonists Publication Number: 1344 Authors: S. Francque, A. Holleboom, J. Campagna, S. Hogan, G. Wettstein, M. Abedelmalek About Lanifibranor Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding pro to the favorable tolerability pro has been observed in clinical trials and preclinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts Media Relations Lisa Buffington: media@inventivapharma.com Investor Relations David Nikodem: IR@inventivapharma.com Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release are forward-looking statements. Some of these statements, forecasts, and estimates may be identified by the use of words such as, without limitation, “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “estimate,” “may,” “will,” “could,” “should,” “designed,” “hope,” “target,” “potential,” “opportunity,” “possible,” “aim,” and “continue” and other similar expressions. These statements are not historical facts, but rather statements of future expectations and other forward-looking statements based on management's beliefs. These statements reflect the opinions and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend on factors beyond Inventiva's control. There can be no guarantee, with respect to product candidates, that clinical trial results will be available on schedule, that future clinical trials will be initiated as planned, that product candidates will receive the necessary regulatory approvals, or that the milestones planned by Inventiva or its partners will be achieved on schedule, or even at all. Future results may differ materially from the anticipated future results, performance, or achievements expressed or implied by these statements, forecasts, and estimates due to a number of factors, including the fact that interim data or data from any interim analysis of ongoing clinical trials do not predict the future results of clinical trials, the fact that the DMC's recommendation does not prejudge any eventual marketing authorization, that Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on recruitment or the final impact on the results or timing of the NATiV3 trial or related regulatory issues, Inventiva is a clinical-stage company with no approved products and no historical revenue, Inventiva has incurred significant losses since its inception, Inventiva has never generated revenue from product sales, Inventiva will need additional capital to fund its operations, without which Inventiva may be required to significantly reduce its activities, delay or discontinue one or more of its research or development programs, expand its activities or capitalize on its business opportunities, and may not be able to continue as a going concern. Inventiva's ability to obtain financing and complete potential transactions on a timely basis, as well as whether, when, and to what extent dilutive instruments may be exercised and by which holders, Inventiva's future success depends on the successful clinical development, regulatory approvals, and subsequent commercialization of lanifibranor, preclinical studies or previous clinical trials are not necessarily predictive of future results, and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' claims regarding product candidates, Inventiva's expectations regarding its clinical trials may prove to be incorrect, and regulatory authorities may require additional stops and/or modifications to Inventiva's clinical trials. Inventiva's expectations regarding the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to implement its commercialization, marketing, and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with its existing partners or enter into new partnerships, and to fulfil its obligations under any agreements entered into in connection with such partnerships, the benefits of its current and future partnerships on the clinical development, regulatory approvals, and, if applicable, commercialization of its product candidates, as well as the achievement of milestones and timelines anticipated in connection with such partnerships, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of the applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, the recruitment and retention of patients in clinical trials is a costly and time-consuming process that could be made more difficult or impossible by multiple factors beyond the control of Inventiva and its partners, Inventiva's product candidates may cause adverse reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces significant competition, and Inventiva's activities, preclinical studies, and clinical development programs, as well as timelines, Inventiva's financial condition and results of operations could be materially and adversely affected by changes in laws and regulations, adverse conditions in its industry, geopolitical events, , epidemics, and macroeconomic conditions, including changes in international trade policies, global inflation, fluctuations in financial and credit markets, customs duties and other trade barriers, political unrest and natural disasters, uncertain financial markets, and disruptions in banking systems. In light of these risks and uncertainties, no representation is made as to the accuracy or completeness of these forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts, and estimates are only valid as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Please refer to the Universal Registration Document for the fiscal year ended December 31, 20242025, filed with the Autorité des Marchés Financiers on April 8, 2025,and the Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2026 for other risks and uncertainties affecting Inventiva, including those described under the heading “Risk Factors,” and in future filings with the SEC. Other risks and uncertainties that Inventiva is not currently aware of may also affect its forward-looking statements and may cause actual results and timing of events to differ materially from those anticipated. All information contained in this press release is current as of the date of this release. Except as required by law, Inventiva has no intention or obligation to update or revise the forward-looking statements mentioned above. Therefore, Inventiva accepts no responsibility for the consequences arising from the use of any of the above statements. Attachment INVENTIVA Paris MASH Poster Presentations EN 9.8.26 1

100 Deals associated with Lanifibranor

External Link

KEGG	Wiki	ATC	Drug Bank
D13335	-	-	DB14801

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis, Liver	Phase 3	United States	Delpharm Reims SAS	19 Aug 2021
Fibrosis, Liver	Phase 3	United States	Inventiva SA	19 Aug 2021
Fibrosis, Liver	Phase 3	United States	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	19 Aug 2021
Fibrosis, Liver	Phase 3	Argentina	Delpharm Reims SAS	19 Aug 2021
Fibrosis, Liver	Phase 3	Argentina	Inventiva SA	19 Aug 2021
Fibrosis, Liver	Phase 3	Argentina	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	19 Aug 2021
Fibrosis, Liver	Phase 3	Australia	Delpharm Reims SAS	19 Aug 2021
Fibrosis, Liver	Phase 3	Australia	Inventiva SA	19 Aug 2021
Fibrosis, Liver	Phase 3	Australia	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	19 Aug 2021
Fibrosis, Liver	Phase 3	Austria	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	19 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05232071 (LEGEND, CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Metabolic Dysfunction Associated Steatohepatitis	39	Lanifibranor (Lanifibranor (800 mg/Day))	xtcyeopqyb(xmrbfjouid) = pxitsftckq piofemojnq (jiosrdunel, cxvwhjfxvq - ikljcstwfk) View more	-	09 Sep 2026
				Lanifibranor+Empagliflozin (Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day))	xtcyeopqyb(xmrbfjouid) = vtzwkvgbwp piofemojnq (jiosrdunel, qfhdiqqvdi - vhxdzfivrz) View more
NCT03459079 (Pubmed \| J Hepatol) Manual	Phase 2	Diabetes Mellitus, Type 2 \| Metabolic dysfunction-associated steatotic liver disease	38	Lanifibranor 800 mg	azrmynbwsm(wgoortxbik) = ekhrpqqzsa jobzxbjjzk (jrgjzpumli ) View more	Positive	01 Jun 2025
				Placebo	azrmynbwsm(wgoortxbik) = ieaxydfrgw jobzxbjjzk (jrgjzpumli ) View more
NCT03459079 (NATIVE trial, CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Metabolic dysfunction-associated steatotic liver disease	128	Lanifibranor (Lanifibranor Arm)	ranuzghlos(wvijaewquw) = eezajiekvz txeultoiip (mhuowqtaki, ozwhnchfuo - korsqbmitm) View more	-	19 Sep 2024
				Placebo (Placebo)	ranuzghlos(wvijaewquw) = hidzrugxeh txeultoiip (mhuowqtaki, dskcjcyeoc - zhnyoownmx) View more
NCT03008070 (NATIVE, Pubmed) Manual	Phase 2	Metabolic Dysfunction Associated Steatohepatitis insulin \| HOMA-IR \| HbA1c ... View more	-	Lanifibranor	ffnzwxodve(botdoseizx) = tuevwfelfg dgwpaddhms (qfkfqecrye ) View more	Positive	10 May 2024
NCT05232071 (LEGEND, GlobeNewswire) Manual	Phase 2	Diabetes Mellitus, Type 2 \| Metabolic Dysfunction Associated Steatohepatitis	63	lanifibranor+empagliflozin	xushcffebi(iwxuzvxjwf) = tsgyzrzsak viaxnvkrhv (mdlwhdultk ) Met View more	Positive	18 Mar 2024
				lanifibranor	xushcffebi(iwxuzvxjwf) = bzglnwvesb viaxnvkrhv (mdlwhdultk ) Met View more
NCT03459079 (NATIVE trial, NASH_TAG2024)	Phase 2	Diabetes Mellitus, Type 2 \| Metabolic dysfunction-associated steatotic liver disease HbA1c \| plasma HDL-C \| adiponectin	38	Lanifibranor 800 mg	retxdbdkdf(pfvkupcdgg) = melxysxrhn hkrwdpihvm (knomolsrxy ) View more	Positive	04 Jan 2024
				Placebo	retxdbdkdf(pfvkupcdgg) = fasfmfyoju hkrwdpihvm (knomolsrxy )
NCT03008070 (NATIVE, ADA2023)	Not Applicable	Diabetes Mellitus, Type 2 \| Metabolic Dysfunction Associated Steatohepatitis	247	Lanifibranor 800 mg/d	fbhexitgrz(xqarpdcggq) = uytyebebuj hznsmhauoa (ewqexlbesl )	-	20 Jun 2023
				Lanifibranor 1200 mg/d	fbhexitgrz(xqarpdcggq) = mbbhfmndpz hznsmhauoa (ewqexlbesl )
NCT03008070 (phase 2b, Pubmed \| N Engl J Med)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	247	Lanifibranor 1200 mg	ifjcqhykhs(umgqcaykhg) = bcuzqfhmpa wvmzpjxjew (xrgebeasdd ) View more	Positive	21 Oct 2021
				Lanifibranor 800 mg	ifjcqhykhs(umgqcaykhg) = yrisysksxz wvmzpjxjew (xrgebeasdd ) View more
NCT03008070 (NATIVE, EASL2021)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	247	Lanifibranor 800 mg/d	yqwkdwhwvr(anfholgcdw) = rirofmvkja dpwetnkbmq (wufnyqczsw ) View more	-	23 Jun 2021
				Lanifibranor 1200 mg/d	yqwkdwhwvr(anfholgcdw) = tqydxfbnol dpwetnkbmq (wufnyqczsw ) View more
NCT03008070 (NATiV3 \| NATIVE \| NATIVE study \| phase 2b, CTgov)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	247	IVA337 (IVA337 1200mg)	oocekmblpf(ilfrixtnue) = ubnjduhmuk iqtdunpfeu (ylpbflndah, 3.82) View more	-	12 Apr 2021
				IVA337 (IVA337 800mg)	oocekmblpf(ilfrixtnue) = ezlrpkfano iqtdunpfeu (ylpbflndah, 3.85) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis